The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Open accessAbstract
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All these effects are consistent with reported roles of APOE4 in inflammation, synaptic impairment, MAPK1 signaling and downstream APP transcription, and early endosomes7,18.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is associated with increased amyloid-β deposition, hyperphosphorylation and aggregation of tau, and accelerated cognitive decline4–7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE4 polymorphism alters the accessibility of the lipid-binding region, which interferes with its cholesterol and lipid transport capacity7.”
From APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“having the APOE ɛ4 coding mutation(s) increases AD risk 3–15 fold [3]”
From Association of SPI1 haplotypes with altered SPI1 gene expression and Alzheimer’s disease risk (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include PLCG2 P522R rare variant (rs72824905) that provides robust protection against AD (odds ratio ≈ 0.68 [1, 4], comparable to having one APOE2 allele [5]”
From PLCγ2 deficiency compromises systemic immune tolerance and erodes myelin homeostasis while enhancing oxidative metabolism in the mouse brain (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE is the most important risk factor for AD and contributes significantly to the risk of developing several other neurological and nonneurological disorders (18).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the APOE-E4 allele confers a ∼ 3.7 times greater risk than the common variant, APOE-E3, whereas homozygous APOE-E4/E4 carriers have a ∼12-15 times greater risk for developing AD.”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE genotype is the strongest genetic risk factor for AD21, with APOE ε2 conferring protection from disease and APOE ε4 conferring higher risk, compared to the APOE ε3 allele”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, binding to LDLR is required by ApoE to perform its downstream effector function (50–52).”
From Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis (2024) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies have consistently implicated immune-related pathways in AD susceptibility, particularly those involving microglial function [21,22].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When activated, microglia, the resident immune cells of the central nervous system, play a central role in amyloid clearance, synaptic remodeling, and the regulation of inflammatory signaling within the brain [21].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APOE gene is a known genetic risk factor for neurodegeneration and cardiovascular disease (CVD) [1, 2].”
From Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants (2023) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 exacerbates amyloid pathology by promoting Aβ production and aggregation, and inhibiting Aβ clearance and degradation”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE4 aggravates the tau pathology via promoting tau phosphorylation, aggregation, propagation, and tau-mediated neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 mediates and regulates the endocytosis of > 30 ligands, including apolipoprotein E (APOE) and amyloid-β (Aβ) [21–27]”
From LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Compared with APOE3, the APOE4 isoform increases AD risk and theAPOE2 isoform reduces AD risk.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“APOE4 isoform may affects the development and progression of AD through multiple different pathways in which inflammatory regulation plays crucial role.166”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that APOE is predominantly expressed in glial cells, particularly astrocytes and activated microglia, which play central roles in A β accumulation, clearance, and neuroin fl ammation 3,4 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Hyperphosphorylated forms of the microtubule-associated protein tau in neurons is a major hallmark of AD [2, 3].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple cohort studies have demonstrated that the APOE ε4 allele is a major genetic risk factor for AD”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“while the three common isoforms (APOE2, APOE3, and APOE4) influence both amyloid‐β–dependent and independent pathways implicated in AD pathogenesis [1, 2].”
From Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype‐Dependent Manner: A Prospective Cohort Study (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“APOE plays a crucial role in the pathophysiology of AD, particularly in relation to Aβ and tau.43,44”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Cerebrovascular dysfunction has been recognized as a major pathological process of AD”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Yamazaki et al 2019
The cited source says what the claim attributes to it.
In the citing paper
“with ApoE4-positive cells showing reduced function (Rawat et al., 2019; Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“ApoE4 shows both loss-of-function and gain-of-toxic-function across various AD pathogenesis pathways (Yamazaki et al., 2019).”
From ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism (2021) · cites this paper as Yamazaki et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, cerebral glucose hypometabolism occurs in both the early stage of AD (Christian et al., 2020; Yamazaki et al., 2019) and epilepsy (McDonald et al., 2018; Patel, 2018).”
From APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice (2026) · cites this paper as Yamazaki et al., 2019
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“We also found that LECs isolated from the meninges of 6-month-old 5xFAD mice showed significant changes in the expression of genes involved in processes such as exocytosis, phospholipase D signaling, and response to low-density lipoprotein (Extended Data Fig. 1f–k), suggesting that meningeal Aβ deposition might affect meningeal LECs early on through deleterious processes previously implicated in”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a specific ApoE4 fragment, ApoE4[Δ(166-299)], has previously been found to promote the cellular uptake of extracellular Aβ42 and resulted in increased oxidative stress [28], similar to the effect of L28P.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“APOE is the most significant known risk factor for sporadic Alzheimer’s disease”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“ApoE4 exhibits the strongest receptor binding and is considered a high-risk allele, while ApoE2 exhibits the weakest receptor binding and is considered protective (Yamazaki et al., 2019).”
From APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases (2024) · cites this paper as Yamazaki et al., 2019
In the citing paper
“APOE also affects tau pathogenesis and tau-mediated neurodegeneration [468].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [468]
In the citing paper
“In fact, 39 AD-associated genes were found within the 10th percentile of highly expressed genes in meningeal LECs, including Apoe, which is intrinsically linked to altered risk for late onset AD15,31 and was one of the few highly expressed genes found at the intersection between all three cell types (Extended Data Fig. 9o).”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Self-citation
Cited by
Sorted by citations
Items 101–200 of 1,006
Fanelli, G., Franke, B., Witte, W. D., Ruisch, I. H., Haavik, J., van Gils, V., Jansen, W. J., Vos, S. J. B., Lind, L., Buitelaar, J. K., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01817-0 · Cited by 91
Yamazaki, Y., Shinohara, M., Yamazaki, A., Ren, Y., Asmann, Y. W., Kanekiyo, T., & Bu, G. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313169 · Cited by 89
Self-citationBlood Biomarkers for Detection of Brain Injury in COVID-19 Patients
DeKosky, S. T., Kochanek, P. M., Valadka, A. B., Clark, R. S. B., Chou, S., Au, A. K., Horvat, C. M., Jha, R. M., Mannix, R., Wisniewski, S. R., et al. (2020) · Journal of Neurotrauma · doi:10.1089/neu.2020.7332 · Cited by 87
Imaging the role of blood–brain barrier disruption in normal cognitive ageing
Verheggen, I. C. M., de Jong, J. J. A., van Boxtel, M. P. J., Postma, A. A., Jansen, J. F. A., Verhey, F. R. J., & Backes, W. H. (2020) · GeroScience · doi:10.1007/s11357-020-00282-1 · Cited by 85
Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study
van Arendonk, J., Neitzel, J., Steketee, R. M. E., van Assema, D. M. E., Vrooman, H. A., Segbers, M., Ikram, M. A., & Vernooij, M. W. (2022) · Brain · doi:10.1093/brain/awac354 · Cited by 85
Effects of intermittent fasting on cognitive health and Alzheimer’s disease
Elias, A., Padinjakara, N., & Lautenschlager, N. T. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad021 · Cited by 85
Isoform- and cell-state-specific lipidation of ApoE in astrocytes
Lindner, K., Beckenbauer, K., van Ek, L. C., Titeca, K., de Leeuw, S. M., Awwad, K., Hanke, F., Korepanova, A. V., Rybin, V., van der Kam, E. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110435 · Cited by 84
APOE ɛ4 dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction
Uchida, Y., Kan, H., Sakurai, K., Horimoto, Y., Hayashi, E., Iida, A., Okamura, N., Oishi, K., & Matsukawa, N. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328519 · Cited by 84
Human microglia maturation is underpinned by specific gene regulatory networks
Han, C. Z., Li, R. Z., Hansen, E., Trescott, S., Fixsen, B. R., Nguyen, C. T., Mora, C. M., Spann, N. J., Bennett, H. R., Poirion, O., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.016 · Cited by 84
Ximerakis, M., Holton, K. M., Giadone, R. M., Ozek, C., Saxena, M., Santiago, S., Adiconis, X., Dionne, D. A., Nguyễn, L., Shah, K. M., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00373-6 · Cited by 81
Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework
Mentis, A. A., Dardiotis, E., & Chrousos, G. P. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0731-7 · Cited by 83
Wang, N., Wang, M., Jeevaratnam, S., Rosenberg, C., Ikezu, T. C., Shue, F., Doss, S. V., Alnobani, A., Martens, Y. A., Wren, M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00577-1 · Cited by 82
Self-citationAPOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1474 · Cited by 81
Activation of endogenous retroviruses during brain development causes an inflammatory response
Jönsson, M. E., Garza, R., Sharma, Y., Petri, R., Södersten, E., Johansson, J. G., Johansson, P. A., Atacho, D. A., Pircs, K., Madsen, S., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106423 · Cited by 80
Huang, Z., Zhao, J., Wang, W. J., Zhou, J., & Zhang, J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00028 · Cited by 80
Naia, L., Shimozawa, M., Bereczki, E., Li, X., Liu, J., Jiang, R., Giraud, R., Leal, N. S., Pinho, C. M., Berger, E., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02289-4 · Cited by 79
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis
Zhang, S., Gao, Y., Zhao, Y., Huang, T. Y., Zheng, Q., & Wang, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00812-5 · Cited by 78
A “multi-omics” analysis of blood–brain barrier and synaptic dysfunction in APOE4 mice
Barisano, G., Kisler, K., Wilkinson, B., Nikolakopoulou, A. M., Sagare, A. P., Wang, Y., Gilliam, W., Huuskonen, M. T., Hung, S.-T., Ichida, J. K., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20221137 · Cited by 78
Three major effects of APOEε4 on Aβ immunotherapy induced ARIA
Foley, K. E., & Wilcock, D. M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1412006 · Cited by 79
Sharma, B., Satija, G., Madan, A., Garg, M., Alam, M. M., Shaquiquzzaman, M., Khanna, S., Tiwari, P., Parvez, S., Iqubal, A., et al. (2022) · Inflammation · doi:10.1007/s10753-022-01730-0 · Cited by 77
Next-generation drug repurposing using human genetics and network biology
Nabirotchkin, S., Peluffo, A. E., Rinaudo, P., Yu, J., Hajj, R., & Cohen, D. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.12.004 · Cited by 77
Integrative metabolomics science in Alzheimer’s disease: Relevance and future perspectives
Lista, S., González‐Domínguez, R., López‐Ortiz, S., González‐Domínguez, Á., Menéndez, H., Martín-Hernández, J., Lucía, A., Emanuele, E., Centonze, D., Imbimbo, B. P., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101987 · Cited by 76
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease
Rego, S., Sánchez, G., & Mesquita, S. D. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00645-0 · Cited by 79
PICALM Rescues Endocytic Defects Caused by the Alzheimer’s Disease Risk Factor APOE4
Narayan, P., Sienski, G., Bonner, J. M., Lin, Y.-T., Seo, J., Baru, V., Haque, A., Milo, B., Akay, L. A., Graziosi, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108224 · Cited by 75
Al‐kuraishy, H. M., Jabir, M. S., Albuhadily, A. K., Al-Gareeb, A. I., & Rafeeq, M. F. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102084 · Cited by 75
White matter injury across neurodegenerative disease
Festa, L. K., Grinspan, J. B., & Jordan‐Sciutto, K. L. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.11.003 · Cited by 80
Emerging Roles of Endothelial Nitric Oxide in Preservation of Cognitive Health
Katusic, Z. S., d’Uscio, L. V., & He, T. (2023) · Stroke · doi:10.1161/strokeaha.122.041444 · Cited by 73
Genomics and Functional Genomics of Alzheimer's Disease
Kamboh, M. I. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01152-0 · Cited by 73
Cashikar, A. G., Toral-Rios, D., Timm, D., Romero, J., Strickland, M., Long, J. M., Han, X., Holtzman, D. M., & Paul, S. M. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100350 · Cited by 72
d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 71
From degenerative disease to malignant tumors: Insight to the function of ApoE
Miao, G., Zhuo, D., Han, X. N., Yao, W., Liu, C., Liu, H., Cao, H., Sun, Y., Chen, Z., & Feng, T. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114127 · Cited by 76
Self-citationTan, L. X., Germer, C. J., Cunza, N. L., & Lakkaraju, A. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101781 · Cited by 71
Vascular ApoE4 impairs behavior by modulating gliovascular function
Yamazaki, Y., Liu, C.-C., Yamazaki, A., Shue, F., Martens, Y. A., Chen, Y., Qiao, W., Kurti, A., Oue, H., Ren, Y., et al. (2021) · Neuron · doi:10.1016/j.neuron.2020.11.019 · Cited by 71
Self-citationAddressing Blood–Brain Barrier Impairment in Alzheimer’s Disease
Sharma, C., Woo, H., & Kim, S. R. (2022) · Biomedicines · doi:10.3390/biomedicines10040742 · Cited by 72
Uchida, Y., Kan, H., Sakurai, K., Oishi, K., & Matsukawa, N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1111448 · Cited by 70
Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J. S., Cho, M., & Hampel, H. J. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01669-5 · Cited by 70
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 70
Jin, Y., Li, F., Sonoustoun, B., Kondru, N. C., Martens, Y. A., Qiao, W., Heckman, M. G., Ikezu, T. C., Li, Z., Burgess, J. D., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02421-8 · Cited by 69
Self-citationRisk factor for Alzheimer’s disease breaks the blood–brain barrier
Ishii, M., & Iadecola, C. (2020) · Nature · doi:10.1038/d41586-020-01152-8 · Cited by 69
Zhou, R., Chen, H.-W., Li, F., Zhong, Q., Huang, Y., & Wu, X. (2023) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2023.05.023 · Cited by 69
Wang, Y., Gao, R., Wei, T., Johnston, L. J., Yuan, X., Zhang, Y., Yu, Z., & Initiative, A. D. N. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05025-w · Cited by 69
“Amyloid‐beta accumulation cycle” as a prevention and/or therapy target for Alzheimer's disease
Rao, C. V., Asch, A. S., Carr, D. J. J., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13109 · Cited by 69
Insel, P. S., Hansson, O., & Mattsson-Carlgren, N. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3780 · Cited by 68
Xu, M., Huang, H., Mo, X., Zhu, Y., Chen, X., Li, X., Peng, X., Xu, Z., Chen, L., Rong, S., et al. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000660 · Cited by 68
Jasiecki, J., Targońska, M., & Wasąg, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042033 · Cited by 67
The Similar and Distinct Roles of Satellite Glial Cells and Spinal Astrocytes in Neuropathic Pain
McGinnis, A., & Ji, R. (2023) · Cells · doi:10.3390/cells12060965 · Cited by 67
Targeting aging and age-related diseases with vaccines
Wu, R., Sun, F., Zhang, W., Ren, J., & Liu, G.-H. (2024) · Nature Aging · doi:10.1038/s43587-024-00597-0 · Cited by 66
Steroids and Alzheimer’s Disease: Changes Associated with Pathology and Therapeutic Potential
Akwa, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134812 · Cited by 66
Peptidyl-Prolyl Cis/Trans Isomerase Pin1 and Alzheimer’s Disease
Wang, L., Zhou, Y., Chen, D., & Lee, T. H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00355 · Cited by 66
Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H
Kotredes, K. P., Oblak, A., Pandey, R. S., Lin, P. B.-C., Garceau, D., Williams, H., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735524 · Cited by 66
La Cunza, N., Tan, L. X., Thamban, T., Germer, C. J., Rathnasamy, G., Toops, K. A., & Lakkaraju, A. (2021) · JCI Insight · doi:10.1172/jci.insight.142254 · Cited by 65
Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups
Kaivola, K., Shah, Z., Chia, R., International LBD Genomics Consortium, Black, S. E., Gan-Or, Z., Keith, J., Masellis, M., Rogaeva, E., Brice, A., et al. (2022) · Brain · doi:10.1093/brain/awab402 · Cited by 65
Intracellular Trafficking Mechanisms of Synaptic Dysfunction in Alzheimer’s Disease
Perdigão, C., Barata, M. A., Araújo, M. N. C. D. F., Mirfakhar, F. S., Castanheira, J., & Almeida, C. G. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00072 · Cited by 66
The Oral–Gut Microbiome–Brain Axis in Cognition
Adil, N. A., Omo-erigbe, C., Yadav, H., & Jain, S. (2025) · Microorganisms · doi:10.3390/microorganisms13040814 · Cited by 65
Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer’s disease
Bhattarai, P., Gunasekaran, T. I., Belloy, M. E., Reyes‐Dumeyer, D., Jülich, D., Tayran, H., Yılmaz, E., Flaherty, D., Turgutalp, B., Sukumar, G., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02721-1 · Cited by 64
The genetic basis for adult onset glaucoma: Recent advances and future directions
Wang, Z., Wiggs, J. L., Aung, T., Khawaja, A. P., & Khor, C. C. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101066 · Cited by 64
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms
Chen, F., Chen, Y., Wang, Y., Ke, Q., & Cui, L. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00316-y · Cited by 63
Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings
Demartini, C., Francavilla, M., Zanaboni, A. M., Facchetti, S., Icco, R. D., Martinelli, D., Allena, M., Greco, R., & Tassorelli, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065334 · Cited by 63
Targeting Microglia-Synapse Interactions in Alzheimer’s Disease
Piccioni, G., Mango, D., Saidi, A., Corbo, M., & Nisticò, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052342 · Cited by 64
He, S., Xu, Z., & Han, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00803-6 · Cited by 62
Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson’s Disease
He, S., Wang, F., Yung, K. K. L., Zhang, S., & Qu, S. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00028 · Cited by 62
Pushing the boundaries of brain organoids to study Alzheimer’s disease
Cerneckis, J., Bu, G., & Shi, Y. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.05.007 · Cited by 63
Self-citationApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
Self-citationPatel, T., Carnwath, T., Wang, X., Allen, M., Lincoln, S., Lewis‐Tuffin, L. J., Quicksall, Z., Lin, S., Tutor‐New, F. Q., Ho, C. C. G., et al. (2022) · Aging Cell · doi:10.1111/acel.13606 · Cited by 61
Si, G., & Álvarez, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21722 · Cited by 61
HDL Proteome and Alzheimer’s Disease: Evidence of a Link
Marsillach, J., Adorni, M. P., Zimetti, F., Papotti, B., Zuliani, G., & Cervellati, C. (2020) · Antioxidants · doi:10.3390/antiox9121224 · Cited by 62
Effects of APOE4 allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice
Miranda, A. M., Ashok, A., Chan, R. B., Zhou, B., Xu, Y., McIntire, L. B., Area-Gomez, E., Di Paolo, G., Duff, K. E., Oliveira, T. G., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01881-6 · Cited by 60
“Co-dominant and additive effects of APOE4 alleles in the EC In terms of AD susceptibility, one copy of APOE4 confers a ~3-fold increased risk, while two copies of APOE4 confers a ~12-fold increased risk of developing AD [14].”
BackgroundApolipoprotein E and viral infection: Risks and Mechanisms
Chen, F., Ke, Q., Wei, W., Cui, L., & Wang, Y. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.031 · Cited by 60
Ferreira, S. T. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12959 · Cited by 59
Jung, M., Lee, S., Park, S., Hong, J., Kim, C., Cho, I., Sohn, H. S., Kim, K. H., Park, I. W., Yoon, S., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207719 · Cited by 59
Mechanisms of neurodegeneration — Insights from familial Alzheimer’s disease
Chávez‐Gutiérrez, L., & Szaruga, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.005 · Cited by 59
Blood-brain barrier models: Rationale for selection
Hanafy, A. S., Dietrich, D., Fricker, G., & Lamprecht, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113859 · Cited by 59
Zhao, J., Lu, W., Ren, Y., Fu, Y., Martens, Y. A., Shue, F., Davis, M. D., Wang, X., Chen, K., Li, F., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02361-9 · Cited by 58
Self-citationCoping with Dementia in the Middle of the COVID-19 Pandemic
Ryoo, N., Pyun, J., Baek, M. J., Suh, J., Kang, M. J., Wang, M. J., Youn, Y. C., Yang, D. W., Kim, S. Y., Park, Y. H., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e383 · Cited by 58
Rapamycin Responds to Alzheimer’s Disease: A Potential Translational Therapy
Hou, S.-J., Zhang, S., Li, Y., & Xu, S.-Y. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s429440 · Cited by 58
A role of low-density lipoprotein receptor-related protein 4 (LRP4) in astrocytic Aβ clearance
Zhang, H., Chen, W., Tan, Z., Zhang, L., Dong, Z., Cui, W., Zhao, K., Wang, H., Jing, H., Cao, R., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0250-20.2020 · Cited by 58
Salvadó, G., Grothe, M. J., Groot, C., Moscoso, A., Schöll, M., Gispert, J. D., Ossenkoppele, R., & Initiative, A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05192-8 · Cited by 57
Guo, J., Brickman, A. M., Manly, J. J., Reitz, C., Schupf, N., Mayeux, R. P., & Gu, Y. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12359 · Cited by 56
Microglial Immunometabolism in Alzheimer’s Disease
Shippy, D. C., & Ulland, T. K. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.563446 · Cited by 56
Oxysterols are potential physiological regulators of ageing
de Médina, P., Silvente‐Poirot, S., & Poirot, M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101615 · Cited by 55
Liu, Y., Gu, X., Li, Y., Wang, F., Vyas, C. M., Peng, C., Dong, D., Li, Y., Zhang, Y., Zhang, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03891-5 · Cited by 55
ApoE4 attenuates autophagy via FoxO3a repression in the brain
Sohn, H.-Y., Kim, S.-I., Park, J.-Y., Park, S.-H., Koh, Y. H., Kim, J., & Jo, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-97117-6 · Cited by 54
The role of glial autophagy in Alzheimer’s disease
Litwiniuk, A., Juszczak, G. R., Stankiewicz, A. M., & Urbańska, K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02242-5 · Cited by 54
Anfray, A., Schaeffer, S., Hattori, Y., Santisteban, M. M., Casey, N., Wang, G., Strickland, M., Zhou, P., Holtzman, D. M., Anrather, J., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01757-6 · Cited by 53
Benzodiazepines in Alzheimer’s disease: beneficial or detrimental effects
Al-Kuraishy, H. M., Al-Gareeb, A. I., Saad, . M., & Batiha, G. E. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01099-4 · Cited by 53
Mitochondrial links between brain aging and Alzheimer’s disease
Wilkins, H., & Swerdlow, R. H. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00261-2 · Cited by 53
Kou, J., Wang, M., Shi, J., Zhang, H., Pu, X., Song, S., Yang, C., Yan, Y., Döring, Y., Xie, X., et al. (2021) · ACS Omega · doi:10.1021/acsomega.0c04810 · Cited by 52
Montal, V., Diez, I., Kim, C.-M., Orwig, W., Bueichekú, E., Gutiérrez-Zúñiga, R., Bejanin, A., Pegueroles, J., Dols-Icardo, O., Vannini, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7273 · Cited by 52
T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer's disease
Zeng, J., Liao, Z., Yang, H., Wang, Q., Wu, Z., Hua, F., & Zhou, Z. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106461 · Cited by 53
In Vivo Chimeric Alzheimer’s Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons
Najm, R., Zalocusky, K. A., Zilberter, M., Yoon, S. Y., Hao, Y., Koutsodendris, N., Nelson, M., Rao, A., Taubes, A., Jones, E. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107962 · Cited by 52
Sex differences in Alzheimer’s disease: metabolic reprogramming and therapeutic intervention
Demetrius, L., Eckert, A., & Grimm, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.09.004 · Cited by 52
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51
Zhang, X., Yuan, T., Chen, X., Liu, X., Hu, J., & Liu, Z. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101256 · Cited by 51
Chai, A. B., Hartz, A. M. S., Gao, X., Yang, A., Callaghan, R., & Gelissen, I. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010246 · Cited by 51
The Functional Roles of Curcumin on Astrocytes in Neurodegenerative Diseases
Mohammadi, A., Colagar, A. H., Khorshidian, A., & Amini, S. M. (2021) · NeuroImmunoModulation · doi:10.1159/000517901 · Cited by 51
Astara, K., Tsimpolis, A., Kalafatakis, K., Vavougios, G. D., Xiromerisiou, G., Dardiotis, E., Christodoulou, G. N., Samara, M. T., & Lappas, A. S. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111899 · Cited by 50
Kršek, A., & Batičić, L. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4020020 · Cited by 50
Detecting Oxidative Stress Biomarkers in Neurodegenerative Disease Models and Patients
Sidorova, Y. A., & Domanskyi, A. (2020) · Methods and Protocols · doi:10.3390/mps3040066 · Cited by 50
A review on neuropharmacological role of erucic acid: an omega-9 fatty acid from edible oils
Kumar, J. B. S., & Sharma, B. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1831262 · Cited by 50
Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease
Serrano-Pozo, A., Li, Z., Noori, A., Nguyen, H. N., Mezlini, A., Li, L., Hudry, E., Jackson, R. J., Hyman, B. T., & Das, S. (2021) · Nature Aging · doi:10.1038/s43587-021-00123-6 · Cited by 49
Metadata
- Authors
- Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G.
- Affiliations
- Mayo Clinic in Florida (US)
- Corresponding author
- Bu, Guojun
- Venue
- Nature Reviews Neurology
- Published
- 2019-07-31
- Volume
- 15
- Issue
- 9
- Pages
- 501-518
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7055192
- OpenAlex
- W2965401191
- Cited by
- 1,425
- References
- 318
- Citations by year
- 2026: 191 · 2025: 259 · 2024: 233 · 2023: 242 · 2022: 200 · 2021: 172 · 2020: 124 · 2019: 4
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (RF1AG051504, R01AG027924, R37AG027924, RF1AG057181, RF1AG046205, R01AG035355)
- National Institute of Neurological Disorders and Stroke (P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, APOE polymorphism, amyloid-beta, tau pathology, neurodegeneration, microglial activation, lipid transport, synaptic plasticity, glucose metabolism, cerebrovascular function, precision medicine
- MeSH terms
- Alzheimer Disease, Apolipoproteins E, Brain, Humans, Polymorphism, Genetic, Amyloid beta-Peptides, Genetic Predisposition to Disease, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
